Cargando…
Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia
Immunoglobulin (Ig) replacement therapy dramatically changed the clinical course of primary hypogammaglobulinemias, significantly reducing the incidence of infectious events. Over the last two decades its use has been extended to secondary antibody deficiencies, particularly those related to hematol...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259107/ https://www.ncbi.nlm.nih.gov/pubmed/25538710 http://dx.doi.org/10.3389/fimmu.2014.00626 |
_version_ | 1782347969165524992 |
---|---|
author | Compagno, Nicolò Malipiero, Giacomo Cinetto, Francesco Agostini, Carlo |
author_facet | Compagno, Nicolò Malipiero, Giacomo Cinetto, Francesco Agostini, Carlo |
author_sort | Compagno, Nicolò |
collection | PubMed |
description | Immunoglobulin (Ig) replacement therapy dramatically changed the clinical course of primary hypogammaglobulinemias, significantly reducing the incidence of infectious events. Over the last two decades its use has been extended to secondary antibody deficiencies, particularly those related to hematological disorders as lymphoproliferative diseases (LPDs) and multiple myeloma. In these malignancies, hypogammaglobulinemia can be an intrinsic aspect of the disease or follow chemo-immunotherapy regimens, including anti-CD20 treatment. Other than in LPDs the broadening use of immunotherapy (e.g., rituximab) and immune-suppressive therapy (steroids, sulfasalazine, and mycophenolate mofetil) has extended the occurrence of iatrogenic hypogammaglobulinemia. In particular, in both autoimmune diseases and solid organ transplantation Ig replacement therapy has been shown to reduce the rate of infectious events. Here, we review the existing literature about Ig replacement therapy in secondary hypogammaglobulinemia, with special regard for subcutaneous administration route, a safe, effective, and well-tolerated treatment approach, currently well established in primary immunodeficiencies and secondary hypogammaglobulinemias. |
format | Online Article Text |
id | pubmed-4259107 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-42591072014-12-23 Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia Compagno, Nicolò Malipiero, Giacomo Cinetto, Francesco Agostini, Carlo Front Immunol Immunology Immunoglobulin (Ig) replacement therapy dramatically changed the clinical course of primary hypogammaglobulinemias, significantly reducing the incidence of infectious events. Over the last two decades its use has been extended to secondary antibody deficiencies, particularly those related to hematological disorders as lymphoproliferative diseases (LPDs) and multiple myeloma. In these malignancies, hypogammaglobulinemia can be an intrinsic aspect of the disease or follow chemo-immunotherapy regimens, including anti-CD20 treatment. Other than in LPDs the broadening use of immunotherapy (e.g., rituximab) and immune-suppressive therapy (steroids, sulfasalazine, and mycophenolate mofetil) has extended the occurrence of iatrogenic hypogammaglobulinemia. In particular, in both autoimmune diseases and solid organ transplantation Ig replacement therapy has been shown to reduce the rate of infectious events. Here, we review the existing literature about Ig replacement therapy in secondary hypogammaglobulinemia, with special regard for subcutaneous administration route, a safe, effective, and well-tolerated treatment approach, currently well established in primary immunodeficiencies and secondary hypogammaglobulinemias. Frontiers Media S.A. 2014-12-08 /pmc/articles/PMC4259107/ /pubmed/25538710 http://dx.doi.org/10.3389/fimmu.2014.00626 Text en Copyright © 2014 Compagno, Malipiero, Cinetto and Agostini. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Compagno, Nicolò Malipiero, Giacomo Cinetto, Francesco Agostini, Carlo Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia |
title | Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia |
title_full | Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia |
title_fullStr | Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia |
title_full_unstemmed | Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia |
title_short | Immunoglobulin Replacement Therapy in Secondary Hypogammaglobulinemia |
title_sort | immunoglobulin replacement therapy in secondary hypogammaglobulinemia |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259107/ https://www.ncbi.nlm.nih.gov/pubmed/25538710 http://dx.doi.org/10.3389/fimmu.2014.00626 |
work_keys_str_mv | AT compagnonicolo immunoglobulinreplacementtherapyinsecondaryhypogammaglobulinemia AT malipierogiacomo immunoglobulinreplacementtherapyinsecondaryhypogammaglobulinemia AT cinettofrancesco immunoglobulinreplacementtherapyinsecondaryhypogammaglobulinemia AT agostinicarlo immunoglobulinreplacementtherapyinsecondaryhypogammaglobulinemia |